MedPath
FDA Approval

Flumazenil

May 31, 2023

HUMAN PRESCRIPTION DRUG LABEL

Flumazenil(0.1 mg in 1 mL)

Manufacturing Establishments (1)

Medical Purchasing Solutions, LLC

Medical Purchasing Solutions, LLC

601458529

Products (1)

Flumazenil

71872-7038

ANDA078527

ANDA (C73584)

INTRAVENOUS

May 31, 2023

EDETATE DISODIUMInactive
Code: 7FLD91C86KClass: IACTQuantity: 0.1 mg in 1 mL
METHYLPARABENInactive
Code: A2I8C7HI9TClass: IACTQuantity: 1.8 mg in 1 mL
Code: 40P7XK9392Class: ACTIBQuantity: 0.1 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACTQuantity: 9 mg in 1 mL
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACTQuantity: 0.1 mg in 1 mL
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
PROPYLPARABENInactive
Code: Z8IX2SC1OHClass: IACTQuantity: 0.2 mg in 1 mL

Drug Labeling Information

INDICATIONS & USAGE SECTION

INDICATIONS AND USAGE

Adult Patients

Flumazenil Injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose.

Pediatric Patients (aged 1 to 17)

Flumazenil Injection, USP is indicated for the reversal of conscious sedation induced with benzodiazepines (seePRECAUTIONS: Pediatric Use).


© Copyright 2025. All Rights Reserved by MedPath